Psychiatr. pro Praxi, 2008; 9(3): 143-146

Kdy volit Stratteru pro léčbu hyperkinetické poruchy/ADHD

prof. MUDr. Ivana Drtílková CSc
Psychiatrická klinika LF MU a FN Brno

Strattera je nový preparát schválený od dubna 2007 pro léčbu dětí s ADHD v České republice. Dosavadní výsledky studií potvrzují, že atomoxetin (Strattera) je srovnatelně účinný s metylfenidátem (Ritalinem) v redukci symptomů u dětí s ADHD. Je známo, že ne všechny děti reagují příznivě na stimulancia a výskyt některých nežádoucích účinků nebo komorbidních poruch omezuje jejich užití. Atomoxetin byl účinný v redukci symptomů ADHD u pacientů s některými komorbidními diagnózami, jako jsou tikové poruchy, úzkostné poruchy, deprese, porucha opozičního vzdoru nebo enuréza. Strattera v dávce jednou nebo dvakrát denně umožňuje dětem vyhnout se stigmatizaci spojené s opakovaným užíváním Ritalinu ve škole. Protože není stimulans, není spojena s rizikem abúzu a drogové závislosti.

Keywords: atomoxetin, metylfenidát, ADHD, děti, indikace, srovnání

Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drtílková I. Kdy volit Stratteru pro léčbu hyperkinetické poruchy/ADHD. Psychiatr. praxi. 2008;9(3):143-146.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Allen AJ, Kurla RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005; 65: 1941-1949. Go to original source... Go to PubMed...
    2. Arnold LE, Aman MG, Cook AM et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006; 45(10): 1196-1205. Go to original source... Go to PubMed...
    3. Biedermann J, Willens T, Mick E et al. Pharmacotherapy of Attention Deficit/Hyperactivity Disorder reduces risk for substance use disorder. Pediatrics 1999; 104(2): 20-26. Go to original source... Go to PubMed...
    4. Drtílková I, Šerý O et al. Hyperkinetická porucha. Praha: Galén 2007; 266 stran.
    5. Drtílková I, Hrdlička M, Paclt I. Hyperkinetické poruchy u dětí. In: Psychiatrie, Doporučené postupy psychiatrické péče II, 2006, 141-149.
    6. Geller D, Donnely C, Lopez F et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety disorder. J Am Acad Child Adol Psychiatry 2007; 46(9): 1119-1127. Go to original source... Go to PubMed...
    7. Jensen PS, Hinshaw SP et al. ADHD comorbidity findings from MTA study: comparing comorbid subgroups. J Am Acad Child Adol Psychiatry 2001; 40: 147-158. Go to original source... Go to PubMed...
    8. Kratochvil Ch, Vaughan B, Mayfield-Jorgessen L. A pilot study of atomoxetine in young children with ADHD. J Child Adol.Psychopharmacology 2007;17(2): 175-185. Go to original source... Go to PubMed...
    9. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with AD/HD. A randomised, placebo-controlled, dose. Response study. Pediatrics 2001; 5 (108): 1-9. Go to original source... Go to PubMed...
    10. Michelson D, AllenA, BusnerJ et al. Once-daily atomoxetine treatment for children and adolescents with ADHD: A randomized, placebo-controlled study. Am. J. Psychiatry 2002; 159(11): 1896-1901. Go to original source... Go to PubMed...
    11. Michelson D, Buitelaar J, Danckaerts M et al. Relapse prevention in pediatric patiens with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J. Am. Acad.Child Adolesc Psychiatry 2004; 43: 896-904. Go to original source... Go to PubMed...
    12. Posey DJ Wiegand RE, Wilkerson J et al. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16(5): 599-610. Go to original source... Go to PubMed...
    13. Polzer J, Bangs M, Zhang S et al. Meta-analysis of agression or hostility events in randomized, controlled clinical trials of atomoxetine for DHD. Biol. Psychiatry 2007; 61: 713-719. Go to original source... Go to PubMed...
    14. Prasad S, Harpin V, Poole L et al. A multi-centre, randomized, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with ADHD. Current Medical Research and Opinion 2007; 23(2): 379-394. Go to original source... Go to PubMed...
    15. Sangal RB, Owens J, Allen A. Effects of atomoxetine and methylphenidate on sleep on children with ADHD. Program and abstracts of the Associated Professional Sleep Societies 18th annual meeting; June 5-10, 2004; Philadelphia, Pennsylvania. Abstract 197.
    16. Sumner C, Wietecha L, Williams DW et al. Atomoxetine for children and adolescents with ADHD and reading disorders. Presented at: The 53rd annual meeting of the American Academy of Child and Adolescent Psychiatry; October 24-29, 2006; San Diego, CA.
    17. Sumner C, Schuh K, Sutton V et al. Controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. Journal of Child and Adolescent Psychopharmacology 2006; 16(6): 699-711. Go to original source... Go to PubMed...
    18. Troost PW, Steenhuis MP, Tuynman-Qua HG et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. J Child Adolesc Psychopharmacol 2006; 16(5): 611-619. Go to original source... Go to PubMed...
    19. Wilens T, Kratochvil Ch, Newcorn J et al. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 2006; 45(2): 149-156. Go to original source... Go to PubMed...
    20. Wilens T, Faraone S et al. Does stimulant therapy of ADHD beget later substance abuse? Pediatrics; 2003, 111: 179-184. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.